Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312801 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
A Phase 1 study of Lymphoma, Non-Hodgkin Lymphoma, B-Cell, sponsored by Luminary Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05312801: Recruiting Phase 1 study of Lymphoma, Non-Hodgkin Lymphoma, B-Cell, sponsored by Luminary Therapeutics.
NCT05312801 is a Phase 1 study of Lymphoma, Non-Hodgkin Lymphoma, B-Cell that is actively recruiting participants, run by Luminary Therapeutics. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05312801, a Phase 1 study of Lymphoma, Non-Hodgkin Lymphoma, B-Cell, is actively recruiting participants, sponsored by Luminary Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Primary Outcome
Maximum tolerated dose.
Conditions Studied
Interventions
- DRUG BAFF CAR-T
Study Locations (2)
Ohio
- University Hospitals Seidman Cancer Center - Cleveland
- Taussig Cancer Institute | Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 1 |
What NCT05312801 shows while recruiting
NCT05312801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Lymphoma, Non-Hodgkin Lymphoma, B-Cell appearing as the primary indexed condition, and to 1 intervention - of which BAFF CAR-T is the first listed.
NCT05312801 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05312801 about?
NCT05312801 is a clinical study titled "Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma". Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractor...
What is the current status of trial NCT05312801?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-11-21. Estimated completion is 2025-09-02.
What conditions does trial NCT05312801 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, B-Cell.
What interventions are being tested in trial NCT05312801?
The interventions under investigation include: BAFF CAR-T (DRUG).
Who is sponsoring clinical trial NCT05312801?
This trial is sponsored by Luminary Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312801 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05312801's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI